Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2022 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference

REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th...
August 29, 2022 20:49 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022, the compensation...
August 04, 2022 16:01 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update

– Commercial launch of CIMERLI™ planned for early October 2022 –– PDUFA date for toripalimab BLA is December 23, 2022 –– Commercial preparation underway for planned July 2023 launch of...
August 02, 2022 19:15 ET | Source: Coherus BioSciences, Inc.

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

- CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023 - - First CIMERLI™ product sales expected in October 2022 - - COLUMBUS AMD...
August 01, 2022 23:15 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 1, 2022, the compensation...
July 28, 2022 16:01 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after...
July 06, 2022 08:00 ET | Source: Coherus BioSciences, Inc.

Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved - REDWOOD CITY,...
June 22, 2022 16:30 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 16, 2022, the compensation committee...
May 11, 2022 18:00 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors

- Dr. O’Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute’s efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May ...
May 10, 2022 08:45 ET | Source: Coherus BioSciences, Inc.

Coherus BioSciences Management to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences...